Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Poor oral health (periodontal disease) impacts nearly 51% of Indians
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The observations are of procedural in nature and will be responded to within the stipulated time
He holds a Master’s in Management from the National University of Singapore
Potential of Ayurveda’s contribution in global health system through various innovative practices
India has taken the lead in recognising NAFLD as a major non-communicable disease
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Subscribe To Our Newsletter & Stay Updated
